Study summary
Selinexor plus ruxolitinib shrank spleens in about half of people, with an early survival signal
49.8%had a 35%+ spleen shrinkage, vs 28.0% with ruxolitinib alone
What was tested
Selinexor, an oral drug that blocks the protein-export pump XPO1, added to ruxolitinib, against ruxolitinib plus placebo, for myelofibrosis not previously treated with a JAK inhibitor.
What they found
- Spleen shrinkage of at least 35% at 24 weeks: 49.8% vs 28.0%.
- Symptom scores improved similarly in both groups, so that co-primary goal was missed.
- An early survival difference was seen (hazard ratio 0.43), though follow-up was only about 12 months.
- Nausea was more common with selinexor, mostly mild.
What it means
A second add-on to ruxolitinib with a clear spleen benefit; longer follow-up will show whether the survival signal holds.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.